Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
But wait, I thought this was launching any day now…
Shareholders have received free spankings out in the shed.
There is no deflection, only selective ignorance from some OTC investors.
Back to my comment on IR basics in doing what a company says it will. This is the cardinal rule in building trust with investors.
Here’s a softball from this year. How many ANDAs did Elite say they will file this year? How many has Elite filed this year or how many are they on track to file by end of next month?
Survey says…let me tally that one for you - zero.
I’m simply much more efficient with my words. Doesn’t take a PhD to realize being verbose without meaning is simply someone wanting to hear themselves talk. (Hint hint)
IR is the only person between investors and C-Suite. There is no one else unless IR team has more than one person. C-Suite or BOD should not be fielding IR questions.
For starters, as I have mentioned many times, effective and trusted leaders do what they say will do. Leaders set a standard and stick to it. They always meet expectations at minimum. Trust is built as expectations are at least met, if not exceeded on a regular basis. This is how confidence is built with investors, lenders, employees, etc. One does not have to search hard to find the many times Elite management has set unrealistic expectations for themselves and completely tripped over that bar.
Lol simply a new username. OTC posters here have been saying NASDAQ for years. CEO has mentioned it several times over the years “when the time is right” to keep OTC investors on the hook.
Successful companies do what they say they will do. This is how confidence within the investment community is built. No need to expound further.
Lol
Like I said, raise of hands for all those who have IR experience. That’s what I thought.
Wasn’t it NASDAQ in 2017?
Not until they can fix their margin issues. The can keeps getting kicked down the road. A plan that can’t be executed is simply a plan. They are becoming a show-me stock. Until margins improve in the financials why trust leadership forecasts if they keep missing them?
Seems like someone falls into that category and is offended. Who all has IR experience at a billion dollar company?
Am I the only one on the board that does?
That’s precisely why you DO NOT communicate in a time of risk. Welcome to the world of communications. Why set the bar high when the bar could get annihilated in 6 months? Welcome to the complex world of investor management.
OTC investors are nothing but armchair quarterbacks that pretend to know everything, yet know nothing.
Why would you be overly optimistic in a PR when the primary revenue stream needs to be replaced within the next 6 months? That makes no sense. Too much is at risk.
What I wouldn’t want to see is Kirkov leaving. That would spell disaster.
This was a PR for the upcoming conference call. Why not wait until the conference call to judge?
Again, Kirkov has absolutely nothing to do with a PR. That’s outside of his swim lane.
Of course they can as long as they make it public. Saying it to one private group of investors would cause an issue.
Kirkov doesn’t write PR’s. That’s typically IR, CFO or CEO.
Most of Elite’s rev is with Adderall. That is tied up until end of March with Lannett. He cannot simply exit this contract. His job will be to execute the bridge to their sales/distribution strategy as seamless as possible. He has very limited products to work with outside Adderall. Once the R&D pipeline shifts more to approvals, then he has more to work with.
Would you reconsider at 0.0356?
It’s a cash flow negative situation when creating your own sales distribution channel. Upfront costs for payback months later. Additional filings now won’t help with the cash flow crunch coming after Lannett deal terminates. Those are next near benefits, if FDA approval process is smooth.
Lannett did fantastic with IR. ER on other hand was pitiful. Company has been able to continue to invest in pipeline and hopefully is starting to move before another round of Covid hits studies, balance sheet is shored up to help weather upcoming transition away from Lannett and we have new chief of sales and CFO. We have some major speed bumps ahead, but think the ship will sail through these rough waters. Seat belts will need to be buckled as there will be some rough spots for sure.
The risk lies in how long it takes to rebuild the upcoming loss of Adderall revenue with Lannett. They can build from scratch or find another distributor, but until that revenue replacement occurs, we have serious risk of a burning cash flow situation. Pipeline isn’t moving fast enough to help offset.
What makes you think he could get 15 cents a share when their major revenue source with Lannett needs to be built from scratch? There’s significant risk here still.
50M is not realistic. 30M annualized will be a stretch goal after they part ways with Lannett since they are going to build sales team from scratch.
Usually it’s a multi year distribution agreement unless during initial ramp months performance is very poor. Gives seller/distributor an out.
Almost to the finish line. Being shelved next to Codeine-acet?
If Nasrat leaves who will continue to hand feed Mikah?
Has nothing to do with greed, but rather the reality of the situation.
One thing that mentioned. Elite has no resources. Not worth including Elite. Nothing to go after. What are they going to take, the fluid bed dryer out of the wall?
There is no indication Lannett is continuing their contract with Elite beyond March. That’s a done deal and companies are parting ways with Adderall distribution.
There still is Vigabatrin that has yet to launch. Bioequivalency trials were completed back in 2018 for this if I remember right offhand. Been a long time.
Oftentimes there is no correlation as their biggest CNS drug isn’t Adderall. However, Adderall was specifically called out in favorable light in both volume and margin profile. That is good news to Elite.
Psst. Nothing will happen by EOD for a company in the generic pharma industry with 1B+ OS.
It is small, but shows that the company is still moving forward. Studies have been delayed for months as Nasrat mentioned on prior calls. Next step is FDA filing. Hopefully this and more FDA submissions will take place next year.
Elite rarely deviates from the SEC filing requirements and wouldn’t expect anything different for this round despite new CFO.
From my IR experience, brokers initially use an estimated date. As time draws closer, the reporting company provides an actual reporting date when results will be released.
“The FDA has encouraged patients affected by the Adderall shortage to work with their healthcare providers to determine the best treatment option, such as switching medications.”
XR sales are pitiful for the market size. Lannett didn’t even come close to making a dent in that market unfortunately. Hopefully Nasrat & Kirkob can do better. IR has had good success, but XR has failed to make any decent market penetration.
Perhaps an increase from public pressure, but this is the government so I wouldn’t be surprised if they don’t do anything either.
Don’t think so. I could be wrong, but I thought there were public remarks that the DEA wasn’t going to increase the quotas.
Why should this next 2 cc’s be any different? Nov & Feb calls will still be under Lannett contract for Adderall. I’d like to hear more about transition readiness, but that’s just sweet talk. Revenue loss avoidance is what we want to see after Lannett contract terminates. Can’t begin to gauge this until Q1 call since contract ends end of Q4 in March.